ReviewFrontiers in oncology2022
Exosome-Based Nanoplatforms: The Emerging Tools for Breast Cancer Therapy.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities.Biomolecules · 2026Review
- Exosomal nanocarriers for targeted drug delivery in cancer therapy.Discover oncology · 2026Review
- Utilizing miR-34a-Loaded HER2-Targeting Exosomes to Improve Breast Cancer Treatment: Insights From an Animal Model.Journal of breast cancer · 2025Article
- Unraveling exosome-mediated cancer therapy resistance: pathways and therapeutic challenges.Journal of the Egyptian National Cancer Institute · 2025Review
- Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.Stem cell research & therapy · 2025Review
- Exosomes and breast cancer angiogenesis; Highlights in intercellular communication.Cancer cell international · 2024Review
- Enhanced anti-tumor efficacy of S3I-201 in breast cancer mouse model through Wharton jelly- exosome.Cancer cell international · 2024Article
- Extracellular Vesicles in Breast Cancer: From Intercellular Communication to Therapeutic Opportunities.Pharmaceutics · 2024Review
- A Nanorobotics-Based Approach of Breast Cancer in the Nanotechnology Era.International journal of molecular sciences · 2024Review
- Different origin-derived exosomes and their clinical advantages in cancer therapy.Frontiers in immunology · 2024Review
- Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis.Journal for immunotherapy of cancer · 2023Article
- Exosomal transfer leads to chemoresistance through oxidative phosphorylation-mediated stemness phenotype in colorectal cancer.Theranostics · 2023Article
- Advances in Purification, Modification, and Application of Extracellular Vesicles for Novel Clinical Treatments.Membranes · 2022Review
- Non-Coding RNAs of Extracellular Vesicles: Key Players in Organ-Specific Metastasis and Clinical Implications.Cancers · 2022Review
- Tumor-Derived Exosomes and Their Role in Breast Cancer Metastasis.International journal of molecular sciences · 2022Review
- Extracellular Vesicle-Mediated Metastasis Suppressors NME1 and NME2 Modify Lipid Metabolism in Fibroblasts.Cancers · 2022Article
- Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions.Antibodies (Basel, Switzerland) · 2022Review
- The application of exosomes in the treatment of triple-negative breast cancer.Frontiers in molecular biosciences · 2022Review
- ExtracellularFrontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) remains the leading malignant tumor type among females worldwide. The patients with BC are still faced with undesirable metastasis, relapse rate, and drug resistance. Exosomes are defined as naturally occurring extracellular vesicles (EVs) with typical biomarkers that reflect the characteristics of the parent cells. Exosomes are crucial mediators involved in intercellular communication. By transferring multiple cargoes, represented by proteins, nucleic acids, lipids, metabolites, exosomes contribute to reshaping the recipient cell function and fate. Growing evidence has documented that exosomes originating from BC cells are important participants involved in BC progression and treatments. Nanoparticle-based technology is the cutting-edge field for renewing pharmaceuticals and has endowed deep improvements in precise BC treatment. Additionally, due to their perfect features of the low immune prototype, limited adverse effects, prolongated circulation, and easy modification, exosomes have received much attention as candidates in nano-medicine of BC. The nanoplatforms constructed by exosomes have safety, intelligence, biomimetic, and controlled released advantages for combating BC. Here, we emphasize the multiple exosomes from a variety of cell sources in constructing nanoplatforms for BC therapy, mainly including exosomes and their cargoes, genetically engineered exosomes, and exosome-based carriers. This field would shed light on the promising exosome-based delivery system in BC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.